Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 7/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 15/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16579352 | 0.84 | NR3C2 (0.47) | NR3C2NR3C1KDM4E | |
| SCHEMBL4309317 | 0.84 | NR3C2 (0.54) | NR3C2NR3C1 | |
| SCHEMBL14488872 | 0.84 | NR3C2 (0.47) | NR3C2NR3C1KDM4E | |
| SCHEMBL8225347 | 0.83 | LMNA (0.47) | NR3C2NR3C1LMNATP53CYP3A4 | |
| SCHEMBL13347573 | 0.83 | NR3C2 (0.49) | NR3C2NR3C1 | |
| SCHEMBL23417033 | 0.82 | NR3C2 (0.44) | NR3C2NR3C1NFE2L2 | |
| Hydrochloric Acid SCHEMBL27481294 | 0.80 | RBP4 (0.40) | NR3C2NR3C1 | |
| SCHEMBL23120088 | 0.80 | RBP4 (0.45) | NR3C2NR3C1LMNA | |
| SCHEMBL29607406 | 0.80 | RBP4 (0.45) | NR3C2NR3C1LMNA | |
| SCHEMBL3882399 | 0.80 | NR3C2 (0.53) | NR3C2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673864-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2022257894-A1 | P300 INHIBITOR AND PHARMACEUTICAL USE THEREOF | 贝达药业股份有限公司 | 2022-12-15 | — | — | WO | disclosed |
| US-20220169645-A1 | COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-06-02 | — | — | US | disclosed |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
| US-20210047271-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2021-02-18 | — | — | US | disclosed |
| US-10738009-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-08-11 | — | — | US | disclosed |
| US-10626111-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190322650-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190248745-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2019-08-15 | — | — | US | disclosed |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2019-03-19 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7179919-B2 | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179919-B2 | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | NR3C2 2113/4885NR3C1 2598/4885LMNA 293/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | NR3C2 150/4885NR3C1 186/4885LMNA 3501/4885 |
| US-20190322650-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | NR3C2 2880/4885NR3C1 2857/4885LMNA 3535/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | NR3C2 3651/4885NR3C1 3460/4885LMNA 2779/4885 |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | NR3C2 109/4885NR3C1 153/4885LMNA 2921/4885 |
| US-20040152736-A1 | Thrombin receptor antagonists | CNR1, TBXA2R, CNR2 | NR3C2 1120/4885NR3C1 1644/4885LMNA 2885/4885 |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | NR3C2 3339/4885NR3C1 3542/4885LMNA 562/4885 |
| US-10738009-B2 | Pyridone amides as modulators of sodium channels | SCN5A, SCN1A, KCNJ2 | NR3C2 2344/4885NR3C1 3679/4885LMNA 1657/4885 |
| US-20220169645-A1 | COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | BTK, LYN, LCK | NR3C2 866/4885NR3C1 451/4885LMNA 3699/4885 |
| US-20210047271-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | NR3C2 2344/4885NR3C1 3679/4885LMNA 1657/4885 |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | NR3C2 440/4885NR3C1 137/4885LMNA 4645/4885 |
| US-11673864-B2 | Pyridone amides as modulators of sodium channels | SCN5A, SCN1A, KCNJ2 | NR3C2 2344/4885NR3C1 3679/4885LMNA 1657/4885 |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | TBXA2R, HTR2C, NPY1R | NR3C2 199/4885NR3C1 301/4885LMNA 1931/4885 |
| US-10626111-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | NR3C2 2544/4885NR3C1 2363/4885LMNA 3485/4885 |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | NR3C2 260/4885NR3C1 796/4885LMNA 419/4885 |
| US-20190248745-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | NR3C2 2344/4885NR3C1 3679/4885LMNA 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.